共 139 条
[1]
Barroso F(2017)Autonomic symptoms in transthyretin amyloidosis: an analysis of symptomatic subjects from the THAOS registry J Peripher Nerv Syst 22 240-204
[2]
Ando Y(2017)Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years Amyloid 24 194-2814
[3]
Gonzalez-Duarte A(2013)Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy J Neurol 260 2802-792
[4]
Schmidt H(2012)Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial Neurology 79 785-924
[5]
Mundayat R(2016)Monitoring effectiveness and safety of tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area J Neurol 263 916-1854
[6]
Barroso FA(2015)Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation 99 1847-36
[7]
Judge DP(2017)Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial Amyloid 24 30-2229
[8]
Ebede B(2016)Schwann cell and endothelial cell damage in transthyretin familial amyloid polyneuropathy Neurology 87 2220-1545
[9]
Li H(2013)Effect on disability and safety of tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy Eur J Neurol 20 1539-1020
[10]
Stewart M(2013)Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis J Cardiovasc Transl Res 6 1011-29